Roche reports strong growth in the first nine months, boosted by diagnostics

20 October 2021
roche_basel_large-1

Roche’s (ROG: SIX) shares were down 1.5% to 390.80 francs in early trading, as the Swiss pharma giant released sales figures for the first nine months of 2021.

Group sales increased by 8% (6% in francs) to 46.7 billion francs ($50.6 billion) in the reporting period, boosted by a strong performance in its diagnostics business. Roche does not release earnings figures on a quarterly basis.

Pharmaceuticals Division sales remained stable at 33.4 billion francs. Since summer there have been signs of recovery from the COVID-19 pandemic and the biosimilar impact is slowing down as expected (Pharma sales: -9% in the first quarter, +4% in the second quarter and +5% in the third quarter).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology